[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 140
1. Baumert H, Ballaro A, Dugardin F, Kaisary AV: Laparoscopic versus open simple prostatectomy: a comparative study. J Urol; 2006 May;175(5):1691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Laparoscopic simple prostatectomy has recently been developed to remove large prostatic adenomas causing bladder outflow obstruction.
  • A Millin and a transvesical-prostatic technique were used in the laparoscopic group and a transvesical technique was used in the open group.
  • RESULTS: There was no significant difference in prostatic size, patient age or body mass index between the 2 groups.
  • In the laparoscopic group the mean International Prostate Symptom score +/- SD improved from 22.4 +/- 6.9 to 5.7 +/- 3.6 and the urinary flow rate improved from 8.1 +/- 2.5 to 24.6 +/- 12.1 ml per minute (each p <0.001).
  • Further studies are indicated to determine whether this technique should be considered the treatment of choice for prostatic adenomas too large for safe endoscopic resection.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600732.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT: Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology; 2009 Jul;74(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
  • OBJECTIVES: To determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention.
  • Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP.
  • METHODS: We performed a review of patients who had undergone transurethral resection of the prostate (TURP; n = 343), holmium laser resection of the prostate (HoLRP; n = 54), or open prostatectomy (OP; n = 68).
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


3. Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Kravchenko Y, Peled R: 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (&gt;4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides. J Endourol; 2009 Jun;23(6):1007-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides.
  • PATIENTS AND METHODS: We included in this study 600 consecutive patients with suspicious findings on a per-rectum examination and/or an elevated prostate-specific antigen (PSA) (>4 ng/mL) level.
  • In all patients, we took from 8 to 16 biopsy samples, according to the prostate volume, from the lateral aspects.
  • TRUS-biopsy detected prostate cancer (PCa) in 257 patients (44.85% overall detection rate).
  • Prostate volumes were significantly smaller (52.9 +/- 22.4 cc vs 58.9 +/- 23.8 cc, P < 0.002) and the PSA/adenoma/prostate volumes ratio (ad-pro) ratio was higher (18.3 +/- 9 vs 13.96, P < 0/001) in the patients with PCa.
  • Patients with PCa underwent fewer biopsy procedures and biopsy sessions than patients without a diagnosis of PCa (14.9 +/- 8.9 vs 20.4 +/- 12, P < 0.001;1.3 +/- 0.6 vs 1.7 +/- 0.9, P < 0.001).
  • Numbers of biopsy procedures and PSA/ad-pro ratio were the strongest predictive factors for PCa detection (P < 0.001).
  • CONCLUSIONS: In patients with a prostate volume >or=53 cc and PSA/ad-pro ratio >or=18, the optimal biopsy cores should be >or=15.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456240.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Chepurov AK, Bulantsev DIu: [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urethra / pathology. Urethra / physiopathology. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472005.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 71
  •  go-up   go-down


5. Martov AG, Ergakov DV: [The experience in dutasteride use before transurethral prostatic resection for large adenoma]. Urologiia; 2008 Jul-Aug;(4):46, 48-50, 52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
  • Dutasterid is a novel effective inhibitor of 5-alpha reductase of both types which can be used in patients with large (more than 80 cm3) prostatic adenoma to prevent intra- and postoperative hemorrhagic complications before transurethral resection of the prostate (TUR).
  • The trial included 70 males aged 67-82 years (mean age 74 years) with large size prostatic adenoma (more than 80 cm3) having indications for prostatic TUR.
  • Patients with coagulopathy, suspected prostatic cancer, previous treatment with 5-alpha reductase inhibitors were not included.
  • We recommend to begin dutasterid administration in a dose 0.5 mg for 1 month before TUR not only for patients with larger prostate (greater than 80 cm3) but with smaller prostates (30-80 cm3) for prevention of hemorrhagic complications and better conditions for surgery.
  • [MeSH-major] Azasteroids / administration & dosage. Enzyme Inhibitors / administration & dosage. Preoperative Care. Prostatic Hyperplasia / surgery. Urogenital Surgical Procedures

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; O0J6XJN02I / Dutasteride
  •  go-up   go-down


6. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


7. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G: Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol; 2008 Oct;22(10):2333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc.
  • CONFLICT OF INTEREST: None Take Home Message: This is a prospective randomized study showing that for large prostatic adenomas, photoselective vaporization of the prostate requires less blood transfusions, shorter catheterization time and shorter hospital stay compared to open prostatectomy, while achieving similar functional results at the same time.
  • AIM: The effectiveness and the safety of photoselective vaporization of the prostate (PVP) was compared to that of open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: 125 patients with prostate glands>80 ml, were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, 12, and 18 months postoperatively.
  • International prostate symptom score (IPSS) and peak urinary flow rate (Qmax) were chosen as primary treatment-related endpoints.
  • At three months prostate volume was significantly lower in the OP group and remained as such throughout follow-up.
  • CONCLUSIONS: Our results indicate that for an 18 month period photoselective vaporization of the prostate is a highly acceptable treatment alternative to open prostatectomy.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837655.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


8. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H, Ogawa H: Is complete resection of hypertrophic adenoma of the prostate possible with TURP? J Nippon Med Sch; 2005 Jun;72(3):146-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is complete resection of hypertrophic adenoma of the prostate possible with TURP?
  • A lot of adenoma remains after transurethral resection of the prostate (TURP), the other hand transurethral enucleation of the prostate (TUE) is useful for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Biomarkers / blood. Humans. Male. Prostate / pathology. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Recurrence

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046830.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


9. Arbuliev MG, Zaĭnulabidov ZSh, Mukhamad II, Arbuliev KM: [A variant of transvesical extraurethral adenomectomy]. Urologiia; 2007 Jul-Aug;(4):37-9, 41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To facilitate extraurethral adenomectomy, we used a semicylindric scalpel and metallic tube (tubus) to make a semioval cut parallel to proximal prostatic portion of the urethra along the posterior semicircle of the bladder neck in 260 patients with prostatic adenoma (PA).
  • Extra-urethral adenomectomy with semicylindric scalpel injured prostatic urethra in lesser extent than endourethral adenomectomy, it reduced the risk of hemorrhage, entailed neither stricture of the posterior urethra nor incontinence of urine in the postoperative period.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urologic Surgical Procedures, Male / instrumentation. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915447.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


10. Davidov MI: [Factors predisposing to acute urine retention in patients with prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors predisposing to acute urine retention in patients with prostatic adenoma].
  • The aim of the trial was to study factors predisposing to acute urine retention (AUR) in patients with prostatic adenoma (PA).
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / epidemiology. Urinary Retention / etiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580384.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


11. Morgunov LIu, Vertkin AL, Pushkar' DIu: [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency]. Urologiia; 2007 Sep-Oct;(5):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Safety of testosterone undecanoate in relation to initiation of cancer and prostatic adenoma (PA) in patients with androgenic deficiency and erectile dysfunction (ED) was studied for 12 months in 49 patients aged 57 to 73 years treated with intramuscular testosteron injections.
  • The size of the prostate in patients with adenoma was 46.34 +/- 21.12 cm3 while in adenoma-free patients--19.11 +/- 6.57 sm3.
  • Thus, long-term therapy with testosterone undecanoate has no effect on PSA level, does not induce urinary obstruction with enlarged prostate.
  • The presence of DM-2 is not a contraindication for androgen therapy in adenoma patients.
  • By reducing body mass index, total cholesterol, triglycerides and LDLP, testosterone therapy lowers the risk of prostatic cancer.
  • [MeSH-minor] Aged. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / diagnosis. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatic Hyperplasia / chemically induced. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / chemically induced. Prostatic Neoplasms / diagnosis


12. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


13. Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology; 2006 Feb;67(2):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity.
  • OBJECTIVES: To elucidate the predictive factors regarding the treatment outcomes after transurethral resection of the prostate for symptomatic benign prostatic enlargement with detrusor underactivity.
  • METHODS: A retrospective study was conducted in 190 patients with detrusor underactivity of 1397 men who had undergone transurethral resection of the prostate.
  • All patients had completed the International Prostate Symptom Score and quality-of-life (QOL) questionnaires and had undergone a full urodynamic analysis before surgery.
  • The outcomes were assessed at 3 and 12 months postoperatively using the International Prostate Symptom Score, QOL score, and peak urinary flow rate.
  • CONCLUSIONS: In selected patients with benign prostatic enlargement associated with detrusor underactivity, greater baseline storage symptom scores and the presence of DO were negative predictive factors for QOL improvement.
  • Baseline DO was also predictive of poorer improvement in the subjective symptoms after transurethral resection of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / complications. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder Neck Obstruction / complications

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461081.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Alivizatos G, Skolarikos A, Chalikopoulos D, Papachristou C, Sopilidis O, Dellis A, Kastriotis I, Deliveliotis C: Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):427-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • OBJECTIVES: To compare the effectiveness and the safety of photoselective vaporization of the prostate (PVP) to open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: A total of 125 patients with prostate glands >80ml were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, and 12 mo postoperatively.
  • International Prostate Symptom Score (IPSS) and peak urinary flow rate (Q(max)) were chosen as primary treatment-related end points.
  • At 3 mo prostate volume was significantly lower in the OP group compared to the PVP group (median value 10ml vs. 50ml; p<0.001) and remained as such throughout follow-up, whereas prostate-specific antigen values reached statistical difference at 6 mo (median value 2ng/ml vs. 2.4ng/ml; p=0.028).
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Aug;54(2):435-6 [18069122.001]
  • [CommentIn] Eur Urol. 2008 Aug;54(2):436-7 [18069121.001]
  • (PMID = 18069117.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Lopatkin NA, Petrov SB, Sivkov AV, Markov AV, Oshchepkov NN, Bolokhanov IuN: [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial]. Urologiia; 2006 May-Jun;(3):3-6, 8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial].
  • Tamsulone-FS--a novel Russian alpha1A/D-adrenoblocker (Farm-Syntez)--was studied in a randomized multicenter comparative trial in patients with prostatic adenoma.
  • Pilot results agreed with other trials published in the literature and demonstrated tamsulone-FS efficacy and safety for management of lower urinary tract symptoms caused by prostatic adenoma.
  • This drug can be recommended for wide clinical practice in prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889080.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


16. Zhao Y, Chen J, Wang M, Sun P, Li L, Zhang H, Jin X: Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients. Saudi Med J; 2010 Dec;31(12):1320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients.
  • OBJECTIVE: To evaluate the safety and effectiveness of the combined photoselective vaporization of the prostate (PVP) and bipolar transurethral resection of the prostate (TURP) in high-risk symptomatic patients with large prostates.
  • One hundred and one patients presenting with various kinds of systematic diseases, and with an American Society of Anesthesiologists score of 3 or greater underwent PVP plus bipolar TURP for severe lower urinary tract symptoms due to benign prostatic hyperplasia with prostatic volume greater than 80 ml.
  • The International Prostate Symptom Score (IPSS) and quality-of-life questionnaire (IPPS-QoL), maximum flow rates (Qmax), postvoid urine residues (PVR), and MRI prostatic volumes were recorded.
  • The mean pre- and post- operative prostate volumes were 102.2 ± 33.1 ml and 40.4 ± 15.6 ml.
  • [MeSH-major] Adenoma / therapy. Prostatic Neoplasms / therapy. Transurethral Resection of Prostate. Volatilization

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21135994.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


17. Martov AG, Merinov DS, Borisenko EA: [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma]. Urologiia; 2006 May-Jun;(3):12-3, 15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma].
  • Clinical efficacy and safety ofplasmakinetic resection and vaporization were studied in 28 patients with prostatic adenoma (mean age 68 years, mean size of the prostate 65 cm3).
  • Complaints by IPSS scale, quality of life index, results of uroflowmetry and prostatic ultrasonography were assessed before surgery (transurethral plasmakinetic resection and prostatic vaporization) and 1, 3, 6 and 12 months after it.
  • Pilot results point to high clinical efficacy and safety of plasmakinetic resection and vaporization in patients with prostatic adenoma.
  • [MeSH-major] Laser Therapy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889082.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


18. Al'-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz'min IV, Chushkin KA: [Prostatilen treatment of prostatic adenoma]. Urologiia; 2006 Nov-Dec;(6):22, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatilen treatment of prostatic adenoma].
  • We studied efficacy of repeated courses of prostatilen in suppositories with dimexide in prostatic adenoma patients with normal micturition.
  • This suggests possibility of suppository prostatilen use not only as an alternative for expensive drugs but also in combination with them in treatment of initial prostatic adenoma.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315707.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Peptides; 0 / Suppositories; 0 / prostatilen; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


19. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C: Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology; 2008 Feb;71(2):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial.
  • OBJECTIVES: To compare the short term outcomes of photoselective vaporization (PVP) and transurethral resection of the prostate (TURP) for glands larger than 70 mL in a prospective randomized trial.
  • METHODS: Seventy-six consecutive patients with enlarged prostatic adenomas of 70 to 100 mL were randomly assigned for surgical treatment with TURP (n = 37) or PVP (n = 39).
  • International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) scores, maximum flow rates (Qmax), postvoid urine residues (PVR), and transrectal ultrasound (TRUS) volumes were recorded.
  • [MeSH-major] Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2008 Sep;72(3):718-9 [18597826.001]
  • (PMID = 18308094.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


20. Cohen RJ, Shannon BA: Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma. Pathology; 2007 Oct;39(5):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Diverticulum / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886106.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


21. Miller AM, Iaroshenko VP, Soroka PV, Stakhnev EIu: [Efficacy of vitaprost forte in patients with prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):50, 52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in patients with prostatic adenoma].
  • The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate.
  • Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069497.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


22. Talmant V, Esposito P, Stilhart B, Mohr M, Tranchant C: [Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Rev Neurol (Paris); 2006 Mar;162(3):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He developed severe urinary disorders increased by a prostatic adenoma which led to surgical treatment.
  • [MeSH-minor] Adenoma / surgery. Antiparkinson Agents / therapeutic use. Biomarkers. Brain / pathology. Brain Chemistry. Combined Modality Therapy. Diagnostic Errors. Disease Progression. Fatal Outcome. Humans. Levodopa / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Parkinson Disease / diagnosis. Parkinson Disease / drug therapy. Parkinson Disease / therapy. Prostatectomy. Prostatic Neoplasms / surgery. Substantia Nigra / pathology. Ubiquitin / analysis. alpha-Synuclein / analysis

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585892.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; Clinical Conference; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Biomarkers; 0 / Ubiquitin; 0 / alpha-Synuclein; 46627O600J / Levodopa
  •  go-up   go-down


23. Shaked G, Czeiger D: Distended urinary bladder and diverticulum-a rare cause of large-bowel obstruction. Am J Surg; 2009 Feb;197(2):e23-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Later the patient underwent surgery to remove an enlarged benign prostatic adenoma, which was the underlying cause of the bladder distention.
  • [MeSH-major] Dilatation, Pathologic / etiology. Diverticulum / complications. Intestinal Obstruction / etiology. Prostatic Hyperplasia / complications. Urinary Bladder Diseases / etiology


24. Sotelo R, Clavijo R, Carmona O, Garcia A, Banda E, Miranda M, Fagin R: Robotic simple prostatectomy. J Urol; 2008 Feb;179(2):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Minimally invasive approaches for large, symptomatic benign prostatic hyperplasia are replacing the gold standard open surgical approach, duplicating its results with lower morbidity.
  • Considerable improvement from baseline was noted in International Prostate Symptom Score (preoperative vs postoperative 22 vs 7.25) and maximum urine flow (preoperative vs postoperative 17.75 vs 55.5 ml per minute).
  • Further publications are expected with larger series and larger prostatic adenomas.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Oct;180(4):1569-70; author reply 1570 [18718613.001]
  • (PMID = 18076926.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Desai MM, Fareed K, Berger AK, Astigueta JC, Irwin BH, Aron M, Ulchaker J, Sotelo R: Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int; 2010 May;105(9):1296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-port transvesical enucleation of the prostate: a clinical report of 34 cases.
  • OBJECTIVE: To present our experience with single-port transvesical enucleation of the prostate (STEP) in 34 patients with large-volume benign prostatic hyperplasia (BPH).
  • The mean prostate volume estimated by transrectal ultrasonography was 102.5 mL and the mean baseline prostate-specific antigen level was 6.7 ng/mL.
  • After establishing pneumovesicum, the prostate adenoma was enucleated transvesically using standard laparoscopic instruments, and the adenoma was extracted in pieces through the port.
  • Digital assistance expedited enucleation of the apical adenoma in 19 (55%) cases.
  • Under pneumovesicum using laparoscopic visualization, the entire adenoma can be effectively enucleated and expeditiously extracted through the novel single port.
  • [MeSH-major] Laparoscopy. Laser Therapy / methods. Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Apolikhin OI, Sivkov AV, Beshliev DA, Abdullin II: [Current opportunities of pharmacotherapy of prostatic adenoma]. Urologiia; 2010 Mar-Apr;(2):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current opportunities of pharmacotherapy of prostatic adenoma].
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-Antagonists / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


27. Borisov VB: [Treatment of prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma].
  • We used lymphotropic therapy in addition to standard treatment in 116 of 232 patients with benign prostatic hyperplasia.
  • Improvement in general condition of the patients, symptoms of infravesical obstruction, size of the prostate, urinary flow rate demonstrated high efficacy of lymphotropic therapy leading to a higher rate of persistent remission and higher quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-1 Receptor Antagonists / therapeutic use. Anti-Bacterial Agents / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967982.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adjuvants, Immunologic; 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Sulfonamides; 57GNO57U7G / Finasteride; EC 3.2.1.- / lidase; EC 3.2.1.35 / Hyaluronoglucosaminidase; G3P28OML5I / tamsulosin
  •  go-up   go-down


28. Kamalov AA, Efremov EA, Dorofeev SD, Mel'nik IaI, Okhobotov DA: [Vitaprost forte in the therapy of patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):39-44, 47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte in the therapy of patients with prostatic adenoma].
  • Active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • Prostatic extract has an organotropic effect in respect to the prostatic gland.
  • It inhibits proliferative activity of cells and, therefore, development of prostatic adenoma, reduces edema and inflammation activity in prostatic diseases.
  • Our study has shown that rectal suppositories vitaprost forte, as monotherapy of prostatic adenoma, produces a statistically significant moderate decrease of prostate size.
  • Rectal suppositories vitaprost forte can be used as monotherapy of prostatic adenoma in patients with moderate infravesical obstruction irrespective of age and concurrent diseases.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Animals. Cattle. Drug Administration Schedule. Humans. Male. Organ Size. Prostate / chemistry. Prostate / pathology. Sulfonamides / administration & dosage. Sulfonamides / therapeutic use. Suppositories. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722619.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Sulfonamides; 0 / Suppositories; 0 / Vitaprost; G3P28OML5I / tamsulosin
  •  go-up   go-down


29. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E, Brenner C: Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res; 2006 Sep 15;66(18):9143-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most importantly, ANT2, but not ANT1, silencing facilitated MMP induction by lonidamine, a mitochondrion-targeted antitumor compound already used in clinical studies for breast, ovarian, glioma, and lung cancer as well as prostate adenoma.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982757.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; 0 / Adenine Nucleotide Translocator 2; 0 / Antineoplastic Agents; 0 / Indazoles; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 8L70Q75FXE / Adenosine Triphosphate; U78804BIDR / lonidamine
  •  go-up   go-down


30. Miller AM: [The experience in postoperative administration of alpha-adrenoblockers]. Urologiia; 2007 Sep-Oct;(5):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study of efficacy of alpha-blocker alfuzosine (dalphaz CP) in a dose 10 mg/day for treatment of postoperative complications after transurethral resection (TUR) of the prostate and open adenomectomy (OAE) and in quality of life (QoL) improvement enrolled 22 patients after TUR of the prostate and 18 patients after OAE.
  • Administration of alpha-blocker on day 1 after surgical treatment of prostatic adenoma leads to earlier regress of urination disorders.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Quinazolines / therapeutic use. Transurethral Resection of Prostate. Urination Disorders / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254227.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 90347YTW5F / alfuzosin
  •  go-up   go-down


31. Lopatkin NA, Maksimov VA, Khodyreva LA, Davydova EN: [Optimisation of early diagnosis of prostatic diseases in megapolis setting]. Urologiia; 2009 Sep-Oct;(5):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimisation of early diagnosis of prostatic diseases in megapolis setting].
  • One of the aims in the strategy of Moscow health service is perfection of early diagnosis of urological diseases.
  • The number of ultrasonographies and transrectal ultrasonic investigations of the prostate rose from 21650 (2002) to 128890 (2007), the number of polyfocal biopsies--from 2165 (2002) to 12219 (2007).
  • The rate of detection of prostatic diseases increased from 1146 cases per 100000 adult male population (1999) to 2097 (2007).
  • Chronic prostatitis was registered in 17.8%, prostatic adenoma in 29.6% examinees, new cases of prostatic cancer were detected in 0.86% examinees.
  • Standard prostatic cancer morbidity rose from 30.4 to 47.0 per 100000 male population.
  • Percentage of early detected prostatic cancer increased from 42.9% in 2000 to 62% in 2007, detection of prostatic cancer stage III-IV reduced from 27.3% in 2000 to 16.6% in 2007.
  • Thus, new prophylactic measures improved efficacy of outpatient urological service, raised rate of detection of chronic prostatitis, prostatic adenoma, prostatic cancer
  • [MeSH-major] Prostatic Diseases / diagnosis. Urban Population
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Moscow / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213912.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


32. Boroian RR: [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma].
  • To determine prognostic factors of lower urinary tract symptoms progression because of prostatic adenoma (PA), we studied content of the basic fibroblast growth factor (bFGF) in blood serum of patients with PA in enzyme immunoassay.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Enzyme Inhibitors / administration & dosage. Fibroblast Growth Factor 2 / blood. Finasteride / administration & dosage. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248600.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 103107-01-3 / Fibroblast Growth Factor 2; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


33. Reich O: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):436-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069121.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Goodman M, Bostick RM, Gross M, Thyagarajan B, Dash C, Flanders WD: Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update. Ann Epidemiol; 2010 Dec;20(12):955-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update.
  • PURPOSE: We previously proposed an oxidative balance score (OBS) and illustrated its practical application by using data from previously completed case-control studies of two neoplasms - sporadic colorectal adenoma and prostate cancer.
  • When the OBS was divided into three approximately equal intervals, a comparison of the lowest to highest category showed similar adjusted ORs (95% CIs) of 0.34 (0.13-0.88) and 0.34 (0.14-0.86) for colorectal adenoma and prostate cancer, respectively.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Mol Carcinog. 2000 Jan;27(1):18-23 [10642433.001]
  • [Cites] Cancer Lett. 2009 Sep 18;282(2):125-36 [19185987.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):773-96 [11375749.001]
  • [Cites] J Nutr. 2002 Apr;132(4):756-61 [11925473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1279-84 [12433703.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:875S-880S [12612173.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):983-92 [15128611.001]
  • [Cites] Cancer Causes Control. 2004 Jun;15(5):493-501 [15286469.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):9-16 [9511847.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):152-8 [9618134.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):325-30 [10453275.001]
  • [Cites] Ann Epidemiol. 2007 May;17(5):394-9 [17462547.001]
  • [Cites] Ann Epidemiol. 2007 Nov;17(11):930; author reply 931 [17855113.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1051-64 [18543072.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1271-9 [11142411.001]
  • (PMID = 21074110.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116795-03; United States / NCI NIH HHS / CA / R01 CA116795; United States / NCI NIH HHS / CA / R01 CA116795-01; United States / NCI NIH HHS / CA / R01 CA116795-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS242540; NLM/ PMC3008422
  •  go-up   go-down


35. Danilov VV, Vasil'chenko AV, Danilova TI, Besedin SA, Borshchenko SA, Danilov VV: [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma].
  • After examination 47 patients with prostatic adenoma (mean age 63 years) received a course of alpha1-adenoblocker (omsulosin in a dose 0.4 mg/day).
  • Thus, long-term treatment with alpha1-adrenoblockers can be used as a pharmacourodynamic test to detect infravesical obstruction in patients with prostatic adenoma.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / diagnosis. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427987.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


36. Hautmann RE, Stein JP: Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am; 2005 May;32(2):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction.
  • The modified procedure includes cystectomy with sparing of prostate, vasa deferens, seminal vesicles, and resection of a prostatic adenoma to avoid bladder outlet obstruction and bladder reconstruction with an orthotopic reservoir.
  • Furthermore, surgeons considering procedures that preserve a portion of the prostatic urethra, the prostatic capsule, or the entire prostate should recognize a 6% risk of significant prostatic cancer in any residual tissue, and the potential risk of urethral tumor involvement with TCC.
  • [MeSH-minor] Humans. Male. Patient Selection. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Seminal Vesicles. Treatment Outcome


37. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


38. Pandak N, Tomić-Paradzik M, Krizanović B, Fornet-Sapcevski J: [The importance of Streptococcus bovis systemic infections]. Lijec Vjesn; 2006 Jul-Aug;128(7-8):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These infections are frequently connected with malignant, potentially malignant, or benign colorectal neoplasia.
  • He was an older man, who had undergone prostatectomy due prostatic adenoma several years before.
  • Histologically, in both cases, those were benign neoplasia.
  • [MeSH-minor] Adult. Aged. Bacteremia / diagnosis. Bacteremia / therapy. Humans. Male. Meningitis, Bacterial / diagnosis. Meningitis, Bacterial / microbiology. Meningitis, Bacterial / therapy

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087134.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


39. Bartoletti R, Cai T, Tinacci G, Longo I, Ricci A, Massaro MP, Tosoratti N, Zini E, Pinzi N: Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator. J Endourol; 2008 Jul;22(7):1509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator.
  • PURPOSE: To evaluate the tolerability and safety of a newly designed probe for trans-perineal microwave thermoablation (TPMT) of the prostate in patients with benign prostatic hyperplasia (BPH), and the in vivo microwave effects on prostatic tissue.
  • Then the International Index of Erectile Function (IIEF-5) and International Prostate Symptom Score (IPSS) questionnaires were administered to each patient at baseline and 1 month after prostatectomy in order to evaluate sexual and urinary function, respectively.
  • The prostatic adenomas were then evaluated by a pathologist.
  • Quasi-spheroid lesions with a well-defined area of complete coagulative necrosis were documented in all removed adenomas 7, 15, and 30 days after TMPT.

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613779.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Hojgaard M, Mikines KJ: Ureteral injuries during photoselective vaporization of the prostate. Scand J Urol Nephrol; 2010 Sep;44(4):265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteral injuries during photoselective vaporization of the prostate.
  • Photoselective vaporization of the prostate is a relatively new surgical modality for male lower urinary tract symptoms.
  • The method has a risk of tissue damage if laser pulses miss the prostatic adenoma and travel through the irrigation fluid in the bladder.
  • Five cases of damage to the ureteral orifices are described, with hidden orifices, intravesical prostatic adenomas and prior prostatectomy as risk factors for laser-related injuries to ureteral orifices.
  • [MeSH-major] Laser Therapy / adverse effects. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Ureter / injuries

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201751.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Shkol'nikov ME, Iakushkin VR: [Diagnosis and treatment of nocturia in patients with prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of nocturia in patients with prostatic adenoma].
  • [MeSH-major] Nocturia / diagnosis. Nocturia / therapy. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248603.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 63
  •  go-up   go-down


42. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


43. Trapeznikova MF, Dutov VV, Dolgovq AG, Urenkov SB: [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis]. Urologiia; 2008 Sep-Oct;(5):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis].
  • We studied efficacy and safety of prostamol-Uno (PU) monotherapy in patients with prostatic adenoma (PA) comorbid with chronic abacterial prostatitis (CAP) in a clinical open trial including 45-year-old males aged over 45 years with PA comorbid with CAP, having irritative and obstructive symptoms by IPSS above 8 points and duration 6 months or longer, by NIH-CPSI above 10 points and duration 3 months or longer.
  • The patients had Qmax from 5 to 15 ml/s, urine volume 100-350 ml, residual urine volume under 150 ml, prostate size more than 25 cm3, PSA level under 4 ng/ml and no bacterial growth in the third urine portion seeding and/or prostatic secretion.
  • The effect was assessed by the disease history, complaints, digital rectal examination of the prostate, the disease symptoms by IPSS, quality of life (QoL), NIH-CPSI, bacteriological tests of the urine and prostatic secretion, urinalysis, Nechiporenko test in 3 urine portions.
  • Uroflowmetry, ultrasonic investigation of the urinary bladder and prostate, transrectal energy dopplerography of the prostate, PSA assay in the blood serum were made in all the patients.
  • Spectral doppler examination detected improvement in prostatic blood flow after PU treatment in 16 (53.3%) patients.
  • Thus, PU effectively reduces irritative and obstructive symptoms typical for prostatic adenoma in combination with CAP.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Blood Pressure / drug effects. Chronic Disease. Electrocardiography. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Quality of Life. Urination / drug effects


44. Martella O, Galatioto GP, Pace G, Vicentini C: PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia. Arch Ital Urol Androl; 2010 Dec;82(4):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia.
  • It is known that serum prostate-specific antigen levels (PSA) decrease gradually following surgery for benign prostatic hyperplasia (BPH), but there is not an established cut-off value for normal PSA after relief of obstruction.
  • We evaluated the impact of prostatic adenoma enucleation on PSA levels in 110 patients who underwent transvesical suprapubic adenomectomy for symptomatic BPH.
  • We examined PSA levels before and after open surgery and weight of the prostatic adenoma as measured by the pathologist.
  • In patients with suspected abnormality on digital rectal examination or PSA > 4.0 ng/mL systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • The mean weight of enucleated adenoma was 87 gr (range 50-201).
  • PSA supernormalisation represents an objective measure of complete adenoma removal.


45. Barrier F, de La Guerenne A, Semjen E, Wierre L, Horrent S, Decaudin B, Resibois JP, Weillaert MP, Azar R, Odou P: [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma].
  • [Transliterated title] Hémophilie A acquise secondaire à un adénome prostatique.
  • Two diagnosis were suspected: a coagulation factor defect, or the presence of a lupus anticoagulant or of anti-factor antibodies.
  • A prostatic adenocarcinoma was suspected: a 5 cm prostatic tumour was found and the PSA level was 113 ng/mL.
  • The patient's disease was identified as a spontaneously acquired haemophilia A associated with prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / complications. Hemophilia A / etiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Anemia / etiology. Diagnosis, Differential. Factor VIII / analysis. Hematoma. Humans. Male. Prostate-Specific Antigen / blood. Triazines

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829479.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Triazines; 55824-91-4 / 4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; 9001-27-8 / Factor VIII; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


46. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


47. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA: Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int; 2006 Jun;97(6):1229-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
  • The authors used preoperative PSA level as a marker of prostate volume and assessed its potential predictive value on the level of clinical efficacy for treating symptomatic BPH.
  • OBJECTIVE: To report the 3-year results and analyse whether total prostate-specific antigen (tPSA) levels and prostate volume before treatment can predict the level of clinical efficacy of photoselective vaporization prostatectomy (PVP) for treating obstructive benign prostatic disease, as high-power potassium-titanyl-phosphate (KTP) laser prostatectomy was previously shown to be safe and to efficiently vaporize prostatic adenoma secondary to benign prostatic hyperplasia (BPH), with minimal bleeding and morbidity.
  • A subanalysis evaluating each patient for tPSA and prostate volume before PVP was conducted, with a long-term assessment of the primary efficacy outcomes at 3 years after PVP.
  • Each subgroup was assessed for changes from baseline in American Urological Symptom Index (AUA SI) score, quality of life (QoL) score, peak urinary flow rate (Q(max)), prostate volume, and postvoid residual urine volume (PVR) at 1, 2 and 3 years after PVP.
  • The mean (sd) prostate volume for group 1 was 48.3 (16.7) mL (87 men), and was 83.1 (30.6) mL (52 men) in group 2.
  • However, the overall results achieved with PVP were very positive and durable to 3 years, irrespective of tPSA level and prostate volume.
  • [MeSH-major] Laser Therapy / methods. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Urologic Diseases / surgery


48. Rehman J, Khan SA, Sukkarieh T, Chughtai B, Waltzer WC: Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques. J Endourol; 2005 May;19(4):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques.
  • PURPOSE: We describe extraperitoneal laparoscopic resection of large prostatic adenomas (<100 g) as an alternative to open simple prostatectomy by both the transcapsular or Millin and the transvesical approaches.
  • PATIENTS AND METHODS: We have performed more than 20 laparoscopic prostatectomies (adenomectomies) for benign prostatic hyperplasia (BPH) for glands >100 g.
  • Using an extraperitoneal approach, enucleation of the obstructing prostatic lobes was performed with the aid of a Harmonic Scalpel and laparoscopic claw forceps.
  • The adenoma removed was approximately 138 g in the first case and 102 g in the second case.


49. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


50. Mazo EB, Krivoborodov GG, Shkol'nikov ME, Efremov NS: [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer]. Urologiia; 2008 Jul-Aug;(4):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer].
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Neuromuscular Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058365.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 37
  •  go-up   go-down


51. Komarov RN, Gordetsov AS, Komarov NV, Kanashkin OV, Svetozrskiĭ NL, Gamaiunov SV: [Urgent problems of prostatic cancer diagnosis in a small district clinic]. Urologiia; 2006 May-Jun;(3):28-9, 31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urgent problems of prostatic cancer diagnosis in a small district clinic].
  • Diagnostic methods in prostatic pathology used in a surgical department of a small town of Pavlovo (Nizhny Novgorod Region) are analysed.
  • Infrared spectroscopy was for the first time used in Pavlovo for diagnosis of cancer.
  • Examination of 57 patients aged 38-89 years has detected prostatic cancer in 16 (28 +/- 5.9%) patients, chronic prostatitis in 6 (10.5 +/- 4%) patients, prostatic adenoma in 34 (59.6 +/- 6.4%) patients, prostatic abscess--in 1 (1.9 +/- 1.7%) patient.
  • Infrared spectroscopy of the blood serum according to the proposed technique provides accurate (91.2 +/- 4.8%, p < 0.01) differential diagnosis of benign and malignant diseases of the prostate.
  • [MeSH-major] Hospitals, District. Prostatic Neoplasms / diagnosis. Spectrophotometry, Infrared / methods
  • [MeSH-minor] Abscess / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male. Middle Aged. Prostatic Diseases / diagnosis. Prostatitis / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889086.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


52. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN, Mosoian MS: [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. Urologiia; 2009 Nov-Dec;(6):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers].
  • Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines--inhibitors of 5alpha-reductase and blockers of alphal-adrenoreceptors.
  • Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin (Gedeon Richter, Hungary).
  • After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 +/- 1.8 to 3.9 +/- 0.9 points, Qmax rose from 8.8 +/- 0.3 to 14.6 +/- 0.3, residual urine volume diminished from 91.7 +/- 8.5 to 31.7 +/- 4.4, the size of the prostate reduced from 72.4 +/- 2.9 to 50.6 +/- 3.7, quality of life improved 2-fold.
  • Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169718.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


53. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression]. Urologiia; 2010 Nov-Dec;(6):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].
  • PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
  • Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively.
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Organ Size. Prostate / drug effects. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Quality of Life. Risk. Treatment Outcome. Urinary Bladder / physiopathology. Urinary Bladder / ultrasonography. Urinary Retention / etiology. Urinary Retention / physiopathology. Urinary Retention / prevention & control. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21433319.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


54. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


55. Modi P, Helfand BT, McVary KT: Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr Urol Rep; 2010 Jul;11(4):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.
  • Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression.
  • However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels.
  • For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume.
  • The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume).
  • In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / therapy


56. Grigor'ev ME, Konorev VA: [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. Urologiia; 2007 Nov-Dec;(6):90, 92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].
  • [MeSH-major] 5-alpha Reductase Inhibitors. Azasteroids / therapeutic use. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652016.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; EC 1.3.99.5 / steroid-5alpha-reductase type 1; EC 1.3.99.5 / steroid-5alpha-reductase type 2; O0J6XJN02I / Dutasteride
  • [Number-of-references] 46
  •  go-up   go-down


57. Avdoshin VP, Andriukhin MI, Mikhaĭlikov TG, Ol'shanskaia EV, Khunov AZ: [Tulozin in combined treatment of patients with acute urinary retention]. Urologiia; 2009 Jul-Aug;(4):11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is much evidence that tulozin promotes recovery of spontaneous urination, Qmax and is effective in combined treatment of patients with acute retention of urine caused by prostatic adenoma.
  • Tulozin is recommended for patients of younger age, with minimal comorbid pathology, hypotonic with orthostatic reactions, history of side effects in the treatment of other alpha-adrenoblockers, in comorbid hypertention, hypercholesterolemia, retrograde ejaculation, low potention, overactive bladder, prostatitis, after prostatic TUR, transvesical adenomectomy.
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prostatic Hyperplasia / therapy

  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824378.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


58. Rasner PI, Pushkar' DIu: [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma].
  • Acute urinary retention in males is often caused by infravesical obstruction due to enlargement of the prostatic gland.
  • Recently it was found that alpha-adrenoblockers promote recovery of physiological voiding in patients with benign prostatic hyperplasia.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / therapy. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Urinary Catheterization. Urinary Retention / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169720.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 0 / Sulfonamides; 90347YTW5F / alfuzosin; G3P28OML5I / tamsulosin
  •  go-up   go-down


59. [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy]. Urologiia; 2009 Mar-Apr;(2):78, 80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy].
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Urinary Bladder, Overactive / physiopathology. Urinary Bladder, Overactive / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526881.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


60. Iwamoto K, Hiraoka Y, Shimizu Y: Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia. J Nippon Med Sch; 2008 Apr;75(2):77-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia.
  • OBJECTIVE: Transurethral enucleation of the prostate (TUE) is designed for complete removal of the prostate lobes.
  • On the basis of TUE and holmium laser enucleation of the prostate, we developed a new technique of transurethral detachment prostatectomy (TUDP) using a tissue morcellator.
  • MATERIALS AND METHODS: In TUDP, enucleation is performed with a prostate-detaching blade and the tip of a resectoscope, followed by removal of the tissue with a morcellator.
  • This study reports our experience with TUDP in which the weight of retrieved tissue was greater than 30 g in 76 patients with benign prostate hyperplasia.
  • RESULTS: The mean preoperative total prostate and adenoma volumes were 70.7 and 47.4 mL, respectively.
  • The mean weight of removed prostate tissue was 61.1 g.
  • The mean preoperative maximum flow rate (Qmax), International Prostate Symptom Score (IPSS), and quality of life score (QOL) improved from 9.8 mL/sec, 20.2, and 4.9, to 22.3 mL/sec, 3.1 and 1.2, respectively.
  • The mean prostate volume and serum prostate-specific antigen level measured 6 months postoperatively in 46 patients were 10.68 mL and 0.89 ng/mL, respectively.
  • CONCLUSIONS: TUDP is effective for complete removal of large prostate lobes in patients with large benign prostate hyperplasia and is associated with lower perioperative morbidity.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Organ Size. Postoperative Complications. Prostate / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18475027.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Aliaev IuG, Grigorian VA, Tsarichenko DG, Lokshin KL, Kharchilava RR: [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control]. Urologiia; 2006 May-Jun;(3):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control].
  • The aim of the study was to improve the results of transurethral prostatic resection (TUPR) by introduction of intraoperative transrectal ultrasonic investigation (TRUSI) and to determine topographic-anatomic features of the prostate, intraorgan relations of adenomatous nodes and surgical prostatic capsule on-line in TUPR.
  • A total of 64 patients with prostatic adenoma (PA) of the second degree aged 52-79 participated in the study.
  • The patients were divided into two study groups (15 patients with volume of the prostate 36.5-78.6 cm3 and 17 patients with prostate size 80-4-141.2 cm3) in which TRUSI was performed and two control groups (n = 14, size 34.9 to 79.2 cm3 and n = 18, size 81.7-130.8 cm3, respectively) who have not undergone intraoperative TRUSI.
  • Control TRUSI on day 7 after TUPR registered mean volume of the prostate to be 19.3 +/- 1.4 cm3 in group 1, 39.8 +/- 2.1 cm3 in group 2, 28.1 +/- 1.6 cm3 in group 3, 47.7 +/- 3.2 cm3 in group 4.
  • Thus, intraoperative TRUSI provides information which helps the surgeon to orient in the course of surgery and minimize the threat of perforation of the prostatic capsule; minimizes intraoperative complications and enhances efficacy of radical transurethral electroresection of prostatic hyperplasia improving long-term outcomes of the operation.
  • [MeSH-major] Intraoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Hyperplasia / ultrasonography. Transurethral Resection of Prostate. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889081.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


62. Trapeznikova MF, Pozdniakov KV, Golubev GV, Terpigorev SA, Agel'tsov MV, Kuznetsov VE, Shvedov MIu: [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease]. Urologiia; 2009 Jan-Feb;(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434906.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


63. Verger-Kuhnke AB, Reuter MA, Epple W, Ungemach G, Beccaría ML: [Photoselective vaporization with the 80-watt KTP-laser (kalium-titanyl-phosphate) and low-hydraulic-pressure TURP in the treatment of BPH: our experience with 230 cases]. Arch Esp Urol; 2007 Mar;60(2):167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La vaporizacion fotoselectiva de la HPB con el KTP-laser (kalium- titanyl-phosphat) de 80 watt y la RTU-P de baja presion hidraulica, experiencia en 230 casos.
  • The additional Resection was carried out in those patients with great adenomas or having a big middle lobe.
  • The group 1 (n: 50) just by laser treatment and small adenomas, the haemoglobin was reduced a 3.2% and nobody required a transfusion.
  • Group 2 (n: 180) with combined treatment of KTP-laser and TUR-P in great adenomas, the haemoglobin was reduced in average 13.7% after the intervention; 2 patients (1.1%) needed a transfusion.
  • CONCLUSION: Our study shows the advantages of combining both, the advantages to combine both surgical procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Laser Therapy / instrumentation. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484484.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


64. Senarriaga Ruiz de la Illa N, Loizaga Iriarte A, Iriarte Soldevilla I, Lacasa Viscasillas I, Unda Urzaiz M: Pelvic hydatid disease as an example of pelvic masses of uncertain aetiology. Actas Urol Esp; 2009 Nov;33(10):1129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other case of pelvic hydatid disease was asymptomatic, and was discovered by chance while examining a 75 year-old man for a prostatic adenoma.
  • The pathology confirmed the diagnosis in the first case and radiological findings confirmed the second.
  • Hydatid disease must be considered in the differential diagnosis of any cystic masses in the pelvic organs, especially in countries where the disease is endemic.
  • [MeSH-major] Echinococcosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096185.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Hawtrey CE, Williams RD: Historical evolution of transurethral resection at the University of Iowa: Alcock and Flocks. J Urol; 2008 Jul;180(1):55-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alcock proclaimed that transurethral resection of the prostate "...cannot be taught and can be learned only by hard, tedious experience."
  • Flocks, added basic science and anatomical knowledge to Alcock's surgical experience to create a body of work that even today provides insight into the complexities of transurethral prostatic resection.
  • MATERIALS AND METHODS: Even as Alcock studied preoperative and postoperative urethrography images to provide demonstration of the enlarged prostate, he firmly believed in the learning curve of surgical proficiency.
  • However, when Alcock and Flocks began studying autopsy material they were able to pinpoint distribution of the prostatic blood supply, and demonstrate techniques to control bleeding and perform transurethral resection in an organized fashion.
  • RESULTS: In his 1932 report to the American Urological Association Alcock detailed not only his surgical success, but also his mortality rate related to resection and prostatic obstruction and its complications.
  • In autopsy specimens with barium sulfate injections into prostatic blood vessels Flocks demonstrated that complete resection of prostate adenoma was possible and produced the desired outcome with good wound healing.
  • CONCLUSIONS: The strong collaboration between Alcock and Flocks, particularly during the 1940s, culminated in a movie presentation of the prostatic resection technique as viewed from inside the bladder antegrade toward the prostate that remains a model for surgical practice today.
  • [MeSH-major] Transurethral Resection of Prostate / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):15-6 [18485411.001]
  • (PMID = 18485410.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Alcock NG; Flocks RH
  •  go-up   go-down


66. Vinarov AZ, Aliaev IuG, Lokshin KL: [Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma]. Urologiia; 2009 Jan-Feb;(1):84, 86-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma].
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Serenoa

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432240.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 19
  •  go-up   go-down


67. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


68. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


69. Razumov SV, Egorov AA: [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
  • A total of 58 patients with prostatic adenoma (PA) treated with prostamol Uno in combination with tamsulosin were divided into two groups: 28 patients continued the above combined therapy, 30 patients were switched to monotherapy with prostamol Uno.
  • All the patients were examined in the course of 4 visits according to standard protocol requesting information on the disease history, complaints, digital rectal examination, IPSS questionnaire, QOL, uroflowmetry with test for residual urine, transrectal ultrasonography of the prostate, blood test for PSA.
  • To the end of treatment month 9 the size of the prostate diminished by 6.7 cm3, on the average, in both groups.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists. Plant Extracts. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724829.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Sergienko NF, Begaev AI, Shchekochikhin AV, Vasil'chenko MI: [Choice of the surgery method in adenoma of the prostate gland]. Voen Med Zh; 2006 Jul;327(7):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choice of the surgery method in adenoma of the prostate gland].
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Humans. Male. Transurethral Resection of Prostate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977877.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


71. Varshney A, Agarwal A: Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world. Indian J Urol; 2009 Jul;25(3):409-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world.
  • Lasers have arrived in a big way for the management of benign prostatic hyperplasia.
  • The most common ones in use are holmium, potassium titanyl phosphate (KTP) and thulium.They remove the prostatic adenoma either by way of enucleation or ablation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1465-9 [12352419.001]
  • [Cites] J Urol. 2000 Jun;163(6):1730-3 [10799170.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):744-9 [17475395.001]
  • [Cites] Eur Urol. 2008 Feb;53(2):382-89 [17566639.001]
  • [Cites] BJU Int. 2007 Sep;100(3):593-8; discussion 598 [17511771.001]
  • [Cites] Curr Opin Urol. 2007 Jan;17(1):27-31 [17143108.001]
  • [Cites] Eur Urol. 2006 Sep;50(3):563-8 [16713070.001]
  • [Cites] BJU Int. 2006 Jan;97(1):85-9 [16336334.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1229-33 [16686717.001]
  • [Cites] J Urol. 2006 Apr;175(4):1428-32 [16516015.001]
  • [Cites] Urology. 2006 Jan;67(1):80-3 [16413337.001]
  • [Cites] J Urol. 2006 Feb;175(2):537-40 [16406990.001]
  • [Cites] J Endourol. 2005 Dec;19(10):1196-8 [16359214.001]
  • [Cites] BJU Int. 2006 Jan;97(1):81-4 [16336333.001]
  • [Cites] J Endourol. 2005 Jun;19(5):550-4 [15989443.001]
  • [Cites] J Urol. 2005 Jul;174(1):210-4 [15947629.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):177-80 [9052466.001]
  • [Cites] J Urol. 1989 Feb;141(2):243-7 [2643719.001]
  • [Cites] J Urol. 2004 Aug;172(2):611-5 [15247744.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1270-4 [14501739.001]
  • (PMID = 19881144.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2779973
  •  go-up   go-down


72. Verger-Kuhnke AB, Reuter M, Epple W, Ungemach G, Beccaría ML: [Combined treatment of prostatic adenoma with the 80 Watt KTP-laser and low-pressure transurethral resection]. Actas Urol Esp; 2006 Apr;30(4):394-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment of prostatic adenoma with the 80 Watt KTP-laser and low-pressure transurethral resection].
  • [Transliterated title] Tratamiento combinado del adenoma prostático con el KPT-láser de 80 Watt y la resección transuretral de baja presión.
  • INTRODUCTION: The purpose of this prospective study is to determine the effectiveness of method for vaporisation and elimination of the prostate adenoma.
  • The additional Resection was carried out in those patients with large adenomas or to have accentuated middle lobule.
  • CONCLUSION: Our study reveals the advantages of combining both operative procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Prostatectomy / methods. Prostatic Neoplasms / surgery. Video-Assisted Surgery / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838611.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Vishnevsiĭ EL, Loran OB, Saenko VS: [Sympathic hyperactivity and reservoir function of the bladder in men]. Urologiia; 2010 Sep-Oct;(5):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group 2 patients (n = 23) with prostatic adenoma have undergone uroflowmetric monitoring before and after treatment with doxasozine (640 uroflowgrams).
  • It may be a humoral process mediated by vasoconstriction and disorder of vesical blood flow.
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged. Aged, 80 and over. Heart Rate / drug effects. Humans. Male. Middle Aged. Organ Size / drug effects. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / physiopathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254643.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


74. Zmerli S: [My life in urology]. Tunis Med; 2008 Nov;86(11):949-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mon vécu de l'urologie.
  • If urinary lithiasis, prostate adenoma, bladder tumor and urethra stricture constituted the majority of my activity, many other diseases specific to the Maghreb should be mentioned such as fistula between bladder and vaginal arising after obstetrical maneuvers and hydatid cyst of the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213482.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Autobiography; Biography; English Abstract; Historical Article; Journal Article
  • [Publication-country] Tunisia
  • [Personal-name-as-subject] Zmerli S
  •  go-up   go-down


75. Weissbach L, Ebert T, Schmitz-Dräger B: [Taking stock after 400 days: the effects on ambulatory care from a medical point of view]. Z Arztl Fortbild Qualitatssich; 2006;100(1):40-3; discussion 44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking the contract signed with the AOK Bavaria and comprising the integrated care of patients with prostate carcinoma, prostate adenoma and prostatitis as an example the contents and consequences of this agreement will be described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524229.001).
  • [ISSN] 1431-7621
  • [Journal-full-title] Zeitschrift für ärztliche Fortbildung und Qualitätssicherung
  • [ISO-abbreviation] Z Arztl Fortbild Qualitatssich
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Bogdanov AB, Luk'ianov IV, Veliev EI: [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
  • Clinical effects and safety of doxazosine + finasteride combination were studied in patients with obstructive and irritative symptoms due to prostatic adenoma (PA).
  • Lower urinary tract symptoms according to IPSS, size of the prostatic gland, Qmax and Qmid, bladder capacity, residual urine volume, blood pressure, PSA level, sexual function, side effects were assessed before and after combined use of the drugs in 30 patients aged 58 to 83 years (mean age 70.5 years).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248599.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


77. Byun SS, Jeong H, Jo MK, Lee E: Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology; 2005 Sep;66(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
  • OBJECTIVES: To investigate the high prevalence of lower urinary tract symptoms in Korean men with a small prostate, we studied the proportions of histologic components of prostatic adenoma in patients with symptomatic benign prostatic hyperplasia.
  • METHODS: Prostatic adenoma specimens were obtained from men with symptomatic benign prostatic hyperplasia who underwent open prostatectomy or transurethral resection of the prostate.
  • Patients were divided into three groups according to the prostate volume as measured by preoperative transrectal ultrasonography (group 1, 20 to 40 cm3, 21 men; group 2, 41 to 80 cm3, 22 men; and group 3, greater than 80 cm3, 23 men).
  • The proportion of the stroma in the prostatic adenoma and the proportions of smooth muscle, collagen types I, II, III, and V, fibronectin, and laminin in stromal tissue were determined using automatic image analyzer quantitatively.
  • RESULTS: The proportions of the stroma in the prostatic adenoma specimens of groups 1 and 2 were significantly greater than in group 3 (P < 0.05).
  • The relative smooth muscle proportion in the prostatic adenoma (proportion of stroma x proportion of smooth muscle in stromal tissue) in groups 1 and 2 was significantly greater than in group 3 (P < 0.05).
  • CONCLUSIONS: These results suggest that the dynamic component of bladder outlet obstruction, which is mediated by smooth muscle tone, may play a more important role in the development of symptomatic benign prostatic hyperplasia in Korean men.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140084.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Bratchikov OI, Ambarian AA, Shumakova EA, Khmaruk AP, Kriukov AA, Trifonov EIu, Mikhaĭlov DV, Abduldzhalil Shukri MA: [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma]. Urologiia; 2010 Jan-Feb;(1):38-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma].
  • The aim of our study was to assess the causes of renal failure in patients with prostatic adenoma (PA) and outcomes after draining of the urinary bladder.
  • We found that age, prostate volume, PA growth pattern, urinary tract infection, concomitant pathology (arterial hypertension, diabetes mellitus, atherosclerosis) do not correlate with a serum creatinine level.
  • [MeSH-major] Creatinine / blood. Prostatic Hyperplasia / complications. Renal Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886730.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


79. Prada Gómez PJ, de la Rua Calderón A, Romo Fonseca I, Evia Suárez M, Abascal García JM, Juan Rijo G, Fernández García J, González Sancho JM, Abascal García R, Rodríguez-Fernández R: High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol; 2005 Oct;7(9):389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
  • INTRODUCTION: It has been well documented that the outcome of prostate cancer treatment depends on the dose administered.
  • Between June 1998 and December 2004, 100 patients with adenoma of the prostate were treated with 46 Gy of external irradiation to the pelvis and 2 HDR brachytherapy fractions (each of 1150 cGy) at the end of weeks 1 and 3 of a 5-week radiotherapy course.
  • CONCLUSIONS: The good results of local control, disease-free survival and few complications that the external radiotherapy combined with HDR brachytherapy have shown suggest that the method should be considered as first-choice in the treatment of prostate tumours of high- and intermediate-risk.
  • [MeSH-major] Brachytherapy / methods. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Disease-Free Survival. Follow-Up Studies. Humans. Male. Postoperative Complications. Prostate / pathology. Prostate / radiation effects. Prostate / surgery. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] Urol Clin North Am. 2001 Aug;28(3):555-65 [11590814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Urology. 2003 Jul;62(1):86-91; discussion 91-2 [12837428.001]
  • [Cites] Radiother Oncol. 2000 Dec;57(3):273-8 [11104885.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1646-9 [15073852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1257-63 [7493850.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):73-81 [9212007.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Arch Esp Urol. 2005 Apr;58(3):213-26; discussion 224 [15906615.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):161-71 [7543891.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):47-54 [8270459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):823-32 [10705002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):359-71 [8420886.001]
  • [Cites] Arch Esp Urol. 1999 Jan-Feb;52(1):32-8; discussion 38-9 [10101885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [Cites] Arch Esp Urol. 1998 Nov;51(9):890-6 [9887562.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):713-25 [7505980.001]
  • [Cites] Urology. 1989 Jul;34(1):1-9 [2749951.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23 ):3904-11 [11099319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):875-9 [8751395.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • (PMID = 16238973.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


80. Bapat S, Umranikar S, Satav V, Bapat A, Joshi A, Ranade G: Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration. Indian J Urol; 2007 Apr;23(2):126-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration.
  • OBJECTIVE: We conducted a study to detect, quantify and compare irrigation fluid absorption in transurethral resection of the prostate (TURP) and Holmium laser enucleation of the prostate (HoLEP), using BEC.
  • MATERIALS AND METHODS: The study included 50 patients of lower urinary tract symptoms, secondary to benign enlargement of prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1989 Feb;141(2):243-7 [2643719.001]
  • [Cites] Acta Anaesthesiol Scand. 1989 Feb;33(2):146-51 [2922983.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(4):245-51 [3101171.001]
  • [Cites] Int Urol Nephrol. 1987;19(2):165-9 [3667130.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):19-26 [3704567.001]
  • [Cites] J Urol. 1969 Dec;102(6):714-9 [4906205.001]
  • [Cites] Br J Urol. 1980 Dec;52(6):526-8 [6161668.001]
  • [Cites] Eur Urol. 1984;10(3):183-6 [6723737.001]
  • [Cites] Lasers Surg Med. 1994;14(3):258-68 [8208052.001]
  • [Cites] Lasers Surg Med. 1996;18(3):278-93 [8778524.001]
  • [Cites] J Endourol. 1998 Jun;12(3):279-82 [9658303.001]
  • [Cites] J Endourol. 1999 Apr;13(3):181-90 [10360498.001]
  • [Cites] J Urol. 1999 Nov;162(5):1640-4 [10524887.001]
  • [Cites] BJU Int. 2000 Jul;86(1):43-6 [10886081.001]
  • [Cites] J Urol. 1958 Mar;79(3):490-9 [13514908.001]
  • [Cites] Surg Clin North Am. 1992 Jun;72(3):531-58 [1589829.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):390-3 [1933159.001]
  • [Cites] J Urol. 1947 Aug;58(2):125-31 [20256856.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):9-17 [2422743.001]
  • (PMID = 19675787.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721519
  • [Keywords] NOTNLM ; Breath ethanol concentration / Holmium laser enucleation of the prostate / fluid absorption / transurethral resection of the prostate
  •  go-up   go-down


81. Martov AG, Merinov DS, Kornienko SI, Gushchin BL, Ergakov DV, Mustafaev EM, Borisenko EA: [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma]. Urologiia; 2006 Mar-Apr;(2):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma].
  • The aim of the study was comparison of urological complications after transurethral resection and its low-invasive alternatives: vaporization, rotoresection, vaporization resection, prostatic incision.
  • Case histories were studied of 5401 patients operated endoscopically for prostatic adenoma in 1991-2003.
  • No hemorrhagic complications occurred in rotoresection, no hemotransfusions were made in vaporization and vaporizing resection, prostatic incision was complicated by hemorrhage only in 0.9% cases.
  • [MeSH-major] Electrosurgery. Postoperative Complications / diagnosis. Postoperative Hemorrhage / diagnosis. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate
  • [MeSH-minor] Humans. Infection / diagnosis. Infection / therapy. Male. Prostatectomy / methods. Treatment Outcome. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708585.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


82. Spivak LG, Demidko IuL, Vinarov AZ: [Thermotherapy with feedback (PLFT) in the treatment of prostatic adenoma]. Urologiia; 2006 Jul-Aug;(4):73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thermotherapy with feedback (PLFT) in the treatment of prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / therapy. Thermography. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058690.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


83. Krivoborodov GG, Mazo EB, Efremov NS: [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases]. Urologiia; 2009 Jan-Feb;(1):13-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases].
  • The new device--CoreFlow Soft Stent--was used for diagnosis of causes of incomplete bladder emptying (IBE) in 19 men with neurogenic diseases.
  • Group 1 consisted of 8 men with IBE and prostatic adenoma.
  • Group 2 consisted of 11 men with IBE but no prostatic adenoma.
  • Different active lengths of the stent are available to match it to the length of the prostatic urethra.
  • The introducer part was then separated from the stent part positioned in the prostatic urethra.
  • Out of 8 patients with prostatic adenoma and neurogenic diseases 4 could urinate with the stent part positioned in the prostatic urethra indicating that prostatic adenoma was the cause for IBE.
  • Our experience indicates that CoreFlow Soft Stent is a simple device for diagnosis of the causes of IBE in men with neurogenic diseases.
  • [MeSH-major] Stents. Urinary Bladder, Neurogenic / diagnosis. Urinary Retention / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432228.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


84. Pushkar' DIu, Loran OB, Petrov SB, Kogan MI, Zhuravlev VN: [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial]. Urologiia; 2008 Jan-Feb;(1):23, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial].
  • Patients with impaired micturition caused by prostatic adenoma received revocarin for 12-weeks.
  • Thus, a 12-week course of revocarin demonstrated good clinical efficacy and safety in patients with urination problems because of prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Urinary Retention / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649675.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


85. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


87. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. Urologiia; 2006 Nov-Dec;(6):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
  • [MeSH-major] Azasteroids / therapeutic use. Cholestenone 5 alpha-Reductase / antagonists & inhibitors. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315721.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Azasteroids; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; EC 1.3.1.22 / Cholestenone 5 alpha-Reductase; O0J6XJN02I / Dutasteride
  • [Number-of-references] 34
  •  go-up   go-down


88. Teodorovich OV, Shatokhin MN, Mal'tsov VN, Konoplia AI, Loktiononv AL, Krasnov AV: [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma]. Urologiia; 2010 Sep-Oct;(5):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma].
  • We compared local immunometabolic effects of two dosage forms of longidase in patients with prostatic adenoma (PA) in combination with chronic prostatitis (CP) in the postoperative period.
  • Transurethral resection (TUR) of the prostate was conducted in 81 patients aged 50-70 years suffering from PA and CP.
  • [MeSH-major] Prostatic Hyperplasia / blood. Prostatic Hyperplasia / immunology. Prostatitis / blood. Prostatitis / immunology


89. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


90. Mazo EB, Sergeeva NA, Grigor'ev ME, Lebedev DV, Solov'eva EV, Konorev VA, Krovets AA: [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer]. Urologiia; 2006 May-Jun;(3):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
  • The aim of the study was to compare diagnostic significance of free PSA (fPSA)/total PSA (tPSA) versus PSA complex with alpha1-antichymotrypsin (cPSA) in tPSA level within 4-10 ng/ml in differential diagnosis of prostatic cancer (PC).
  • A complete urological examination (digital rectal test, transrectal ultrasound investigation, serum assay for fPSA and tPSA, multifocal transperineal prostatic biopsy) was made in 108 patients with tPSA blood level 4-10 ng/ ml.
  • Prostatic adenoma (PA) was histologically verified in 61 of 108 patients, fPSA/tPSA was normal.
  • A course of etiotropic therapy of chronic prostatic inflammation produced no significant changes in fPSA/tPSA and cPSA in 28 out of 39 patients.
  • Thus, cPSA in PC suspects is more informative than fPSA/tPSA in PC diagnosis.
  • CPSA in the serum depends on prostatic inflammation making difficult differential diagnosis of PC in interpretation of tPSA, fPSA/tPSA and cPSA.
  • Therefore, estimation of PSA variants and molecular forms in PC suspects and prostatic inflammation should be made after etiotropic therapy.
  • [MeSH-major] Antigens, Surface / blood. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. alpha 1-Antichymotrypsin / blood


91. Protogerou V, Argyropoulos V, Patrozos K, Tekerlekis P, Kostakopoulos A: An alternative minimally invasive technique for large prostates (&gt;80 mL): transvesical prostatectomy through a 3-cm incision. Urology; 2010 Jan;75(1):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 165 patients with benign prostatic hyperplasia were treated with transvesical prostatectomy through a 3-cm incision.
  • Prostate size was 85-144 cm(3) (mean 101 cm(3)).
  • Prostate adenoma was removed with finger dissection without the placement of hemostatic sutures.
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2011 Mar;77(3):768; author reply 768-9 [21377027.001]
  • (PMID = 19896175.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Błaut K, Wiśniewski P, Syrenicz A, Sworczak K: Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog. Neuro Endocrinol Lett; 2006 Oct;27(5):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
  • LHRH analogs have become a promising modality in prostate cancer therapy as an alternative to surgical castration, and the use of these agents is generally considered to be safe.
  • Since now, only few cases of an apoplexy of previously undiagnosed pituitary adenoma (usually gonadotropinoma) at the beginning of therapy have been described in the medical literature.
  • We present a case of a 74 year old patient who was diagnosed of prostate cancer at the age of 68.
  • During 6 years of follow-up there was no evidence of prostate cancer recurrence.
  • [MeSH-major] Adenoma / complications. Gonadotropin-Releasing Hormone / analogs & derivatives. Neoplasms, Multiple Primary / diagnosis. Pituitary Apoplexy / etiology. Pituitary Neoplasms / complications. Prostatic Neoplasms / drug therapy


93. Sitdykova ME, Zubkov AIu: [Efficacy of vitaprost forte in the treatment of prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in the treatment of prostatic adenoma].
  • Thirty patients with a documented diagnosis of prostatic adenoma were treated with vitaprost forte (100 mg rectal suppositoria) for 60 days.
  • Its efficacy was proved by improved urodynamics of the lower urinary tract, reduction of prostatic size.
  • Vitaprost forte is recommended for treatment of patients suffering from prostatic adenoma with mild and moderate symptoms.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169719.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


94. Gorilovskiĭ LM, Zingerenko MB, Lakhno DA: [Efficacy of setegis administration after transvesical adenomectomy]. Urologiia; 2007 Nov-Dec;(6):61, 63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prazosin / analogs & derivatives. Prostatic Hyperplasia / surgery. Urination / drug effects. Urination Disorders / drug therapy. Urologic Surgical Procedures, Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649663.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 8L5014XET7 / Terazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


95. Morozov AP, Trapeznikov MF, Kushlinskiĭ NE: [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma].
  • We compared serum levels of insulin-like growth factors (IGF) type 1 protein (IGFP-1) in prostatic cancer (PC) and prostatic adenoma (PA).
  • Sensitivity and specificity of IGFP-1 estimation for differential diagnosis of PC were 72.1 and 57.1%, respectively), of IGFP-1/PSA for differential diagnosis was 81.3 and 87.5%, respectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Insulin-Like Growth Factor Binding Protein 1 / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580387.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


96. Malek RS: [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma]. Urologiia; 2006 Sep-Oct;(5):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma].
  • Novel laser technologies were used in development of a new highly effective and simple method of laser adenomectomy (LA) called photoselective vaporization of the prostate (PVP).
  • Efficacy of PVP is comparable to transurethral resection (TUR) of prostatic adenoma but is more cost-effective than TUR or other low-invasive techniques.
  • Therefore, PVP is very promising in surgical treatment of obstructive prostatic adenoma and may become a leading surgical method in this disease.
  • [MeSH-major] Laser Therapy. Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Animals. Humans. Male. Phosphates. Potassium Compounds. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIPOTASSIUM PHOSPHATE .
  • Hazardous Substances Data Bank. MONOPOTASSIUM DIHYDROGEN PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444145.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Phosphates; 0 / Potassium Compounds; 16068-46-5 / potassium phosphate
  •  go-up   go-down


97. Tkachuk VN, Tkachuk IN: [Vitaprost forte efficacy in patients with prostatic adenoma]. Urologiia; 2008 Jul-Aug;(4):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte efficacy in patients with prostatic adenoma].
  • Efficacy and safety of a new bioregulatory peptide vitaprost forte was studied in 30 patients with prostatic adenoma.
  • It is shown that this drug relieves clinical symptoms of the disease, improves quality of life, uroflowmetric parameters, reduces the size of the prostatic gland.
  • Vitaprost forte is more effective in patients with prostatic adenoma combined with chronic prostatitis.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Aged. Chronic Disease. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate / pathology. Prostate / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058362.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


98. Shakhmachev VN: [Comparative evaluation of hemostatic methods during open adenomectomy]. Urologiia; 2010 Nov-Dec;(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The article compares effectiveness of different methods of hemostasis after transvesical adenomectomy for prostatic adenoma practiced in the world and presents original experience in surgical treatment of 224 patients with prostatic adenoma.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Hemostasis, Surgical / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427988.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


99. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN: [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection]. Urologiia; 2008 Jan-Feb;(1):27, 29, 31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection].
  • Finasteride effect before transurethral resection (TUR) of the prostatic gland was studied in 88 patients with prostatic adenoma (PA).
  • Finasteride reduced blood flow in prostatic tissue, density of the vascular plexus, epithelium/stroma coefficient from 1.26 to 0.84.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Preoperative Care. Prostate / surgery. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652018.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


100. Zhang Y, Du CJ, Xu G, Chen JM, Jing X: [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. Zhonghua Nan Ke Xue; 2007 Dec;13(12):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g].
  • OBJECTIVE: To evaluate the effect of transurethral holmium laser enucleation of the prostate (HoLEP) for prostate adenoma greater than 100 g.
  • METHODS: Sixty BPH patients with the prostate larger than 100 g were randomized to two treatment groups of HoLEP (n = 32) and open prostatectomy (n = 28).
  • Comparisons were made between the two groups in operating time, blood loss, bladder irrigating time, catheterization time and hospital stay, as well as in the international prostate symptom score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax) and postvoid residual volume (PVR) before and 3 months after the surgery.
  • CONCLUSION: HoLEP and open prostatectomy are equally effective procedures for removal of large prostate adenomas, but the former is a better surgical option for prostate adenomas larger than 100 g for its greater safety, less pain and faster recovery.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284057.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  •  go-up   go-down






Advertisement